Self-expandable valve-in-valve treatment for failing sutureless aortic bioprosthesis

Research output: Contribution to journalArticlepeer-review


Aortic valve replacement still represents the gold standard treatment for severe symptomatic aortic stenosis. Sutureless bioprostheses have been so far developed to enhance the minimally invasive approach, resulting in a reduction of cross-clamp time. Even if the first implantation was carried out more than 10 years ago, some cases of valve degeneration treated with balloon-expandable valve-in-valve procedures have been previously described in the literature. Here, we present a case of early sutureless valve degeneration resulting in severe aortic regurgitation. After careful evaluation of the patient's comorbidities, a successful valve-in-valve was finally performed using a self-expandable transcatheter prosthesis. A wide discussion of the Heart Team decision-making process and of the technical aspects has been addressed.

Original languageEnglish
Pages (from-to)477-479
Number of pages3
JournalJournal of Cardiac Surgery
Issue number2
Publication statusPublished - Feb 1 2020


  • SAVR
  • sutureless
  • TAVI
  • valve-in-valve

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Self-expandable valve-in-valve treatment for failing sutureless aortic bioprosthesis'. Together they form a unique fingerprint.

Cite this